| Aims: To assess the different treatment methods in management of neurogenic
bladder (NGB) in patients with Parkinson's disease (PD).
Methods: A systematic search was performed in Cochrane library, EMBASE,
Proquest, Clinicaltrial.gov, WHO, Google Scholar, MEDLINE via PubMed, Ovid,
ongoing trials registers, and conference proceedings in November 11, 2017. All
randomized controlled trials (RCTs) or quasi-RCTs comparing any treatment method
for management ofNGBin patients with PD were included. The titles and abstracts of
all identified studies were evaluated independently by two investigators. Once all of
the potential related articles were retrieved, each author separately evaluated the full
text of each article and the quality of the methodology of the selected studies using the
Cochrane appraisal risk of bias checklist and then the data about the patient's
outcomes was extracted.We registered the title in Joanna Briggs Institute (JBI) that is
available in http://joannabriggs.org/research/registered_titles.aspx.
Results: We included 41 RCTs or quasi-RCTs or three observational study with a
total of 1063 patients that evaluated pharmacological, neurosurgical, botulinum
toxin, electrical neuromodulation, and behavioral therapy effects on NGB. Among
the included studies only solifenacin succinate double-blind, randomized, placebocontrolled
study was assessed as low risk of bias, and treatment led to an improvement
in urinary incontinence.
Conclusions: Although several interventions are available for treatment NGB in
patients with PD, at present there is little or no evidence that treatment improves
patient outcomes in this population. Additional large, well designed, randomized
studies with improved methodology and reporting focused on patient-centered
outcomes are needed. |